CBER/CDER Transition Begins In June: Application Assignments “99.99%” Set
Executive Summary
The reorganization of the Center for Biologics Evaluation & Research and Center for Drug Evaluation & Research is scheduled to take effect on June 30 with the detailing of approximately 200 employees from CBER to CDER
You may also be interested in...
Could US FDA Move Gene Therapy Regulation To Device Center In Years To Come?
CBER Director Peter Marks said more sophisticated manufacturing expected in the next decade could lead to questions about whether gene therapies should be regulated by his center or CDRH.
CDER Office Of Biotech Products To Oversee Biologics Quality After Transition
Center for Drug Evaluation & Research Office of New Drug Chemistry Director Yuan-yuan Chiu, PhD, will serve as acting director of FDA's Office of Biotech Products when the office is officially established in October
Generic Biologics On FDA Fast Track?: “Follow-On” Process Under Debate
Data requirements for generic biologics approved under the 505(b)(2) process will be taken up by FDA over the next six months, Center for Drug Evaluation & Research Director Janet Woodcock, MD, said